Clinical Trials

The purpose of this study is to compare the gut bacterial and fungal microbiota profiles of patients with poorly-controlled asthma and patients with well-controlled asthma. 

The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in adolescents and adults (12 years of age and older) taking inhaled formoterol fumarate/fluticasone propionate combination is the same as those taking inhaled fluticasone propionate alone.

The purpose of this study is to evaluate the effectiveness and safety of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma by measuring it on markers of asthma control. The overall intent of the current study is to more fully explore the impact of mepolizumab on health-related quality of life and other measures of asthma control, including lung function.

The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with uncontrolled, severe asthma with eosinophilic inflammation. A subset of patients will take part in body plethysmography substudy to further investigate the effect on lung function.

Can a clinical test be developed that could help manage asthma symptoms?

Advisory Committee for Immunization Practices (ACIP) from the Centers for Disease Control (CDC) recommends that children (6-18 years) and adults (≥19 years old) with chronic lung condition such as asthma or cigarette smoking be vaccinated with Pneumococcal vaccine (PPSV23). The purpose of this study is to increase awareness of vaccination to late adolescents with asthma and smokers (social aspect of study), and to recommend vaccination (which is the clinical aspect). Individuals who agree to receiving vaccine will be enrolled in research to determine whether late adolescents with and without asthma (smokers) have distinctive pneumococcal vaccine response patterns and whether such ...

Study drug and placebo will be supplied in Teva multidose dry powder inhaler (MDPI) devices and provided for participants to use at home. Participants will perform spirometry at every visit. Each participant will be given a diary at each visit for use until the next visit. Rescue medication (albuterol/salbutamol) will be dispensed at each visit, if needed, as determined by the investigational center personnel.

The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.

The purpose of this study is to provide asthma management in the retail clinic setting in order to increase standardized asthma quality metrics in the Mayo Clinic Rochester Employee and Community Health asthma patient population.

The purpose of this study is for patients who have decreased their chronic asthma medications to collect periodic home nasal swabs that measure levels of airway inflammation and may predict their asthma stability.

Asthma is the most common chronic condition in children and one of the five most burdensome diseases in the United States. However, research and care for childhood asthma is limited by an inefficient use of electronic medical records to assist with large-scale studies and care. The purpose of this study is to test the use and effectiveness of the asthma-Guidance and Prediction System (a-GPS) within the Asthma Management Program, a current care coordination program for the asthma care of children aged 5-17 years at Mayo Clinic.

Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.

The purpose of this study is to develop an Olmsted County nitrogen dioxide (NO2) model by assessing residential levels of indoor (eg, from gas stove or oven) and outdoor NO2 (eg, from motor fuels and power plants) using passive monitors placed for a 4-week period.

The purpose of this study is to look to see if automated chart review by computer predicts asthma status and asthma status characterization.

The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor study D3250C00021 (BORA).

The purpose of this study is to identify a new population of cells in the blood that may be contributing to allergic inflammation in atopic asthmatics.

The purpose of this study is to identify gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA), and to determine the composition of immune cells present in the microenvironment of individuals with SEA after initiation of mepolizumab.

Primary objective of the study is to evaluate whether patients with severe eosinophilic asthma who have received long-term treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to receive benefit.

The purpose of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week washout.

This research study is being done for people who have asthma and chronic rhinosinusitis, hay fever, or you do not have any sinus disease, asthma or hay fever (control). The aim of the study is to investigate the functions of nasal epithelial cells.

The purpose of this study is to obtain breath acoustic recordings and measures of lung mechanics in patients with COPD, asthma, and cystic fibrosis breathing at rest and during light submaximal exercise. The plan is to examine these respiratory acoustics and mechanics in relation to determinants of disease and/or disease states (classic respiratory pathophysiology) and quality of life measures in these patient populations to determine if any relationship or patterns exist when comparing across respiratory diseases and within a condition based on disease severity.       

The purpose of this study is to investigate the effect of benralizumab on the rate of asthma exacerbations, patient reported quality of life and lung function during 24-week treatment in patients with uncontrolled, severe asthma with eosinophilic inflammation. A subset of patients will be assessed for their ongoing chronic rhinosinusitis with nasal polyps.